Advertisement
Screener

Savara Inc (SVRA) Shareholder Equity

Savara Inc (SVRA) Shareholder Equity

  • 2026-06-30: Common Stock, Value, IssuedUSD $204.00K; Additional Paid in Capital, Common StockUSD $829.59M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-534.00K; Retained Earnings (Accumulated Deficit)USD $-685.60M.
  • 2026-03-31: Common Stock, Value, IssuedUSD $204.00K; Additional Paid in Capital, Common StockUSD $821.63M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-429.00K; Retained Earnings (Accumulated Deficit)USD $-645.37M.
  • 2025-12-31: Common Stock, Value, IssuedUSD $204.00K; Additional Paid in Capital, Common StockUSD $811.10M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-87.00K; Retained Earnings (Accumulated Deficit)USD $-608.09M.
  • 2025-09-30: Common Stock, Value, IssuedUSD $173.00K; Additional Paid in Capital, Common StockUSD $670.22M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-155.00K; Retained Earnings (Accumulated Deficit)USD $-575.85M.

Savara Inc Shareholder Equity

Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.

Period endCommon Stock, Value, Issued
USD
Additional Paid in Capital, Common Stock
USD
Accumulated Other Comprehensive Income (Loss), Net of Tax
USD
Retained Earnings (Accumulated Deficit)
USD
Stockholders' Equity Attributable to Parent
USD
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest
USD
APIC, Share-based Payment Arrangement, Increase for Cost Recognition
USD
Treasury Stock, Value
USD
Treasury Stock, Retired, Cost Method, Amount
USD
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
USD
APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
USD
Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
USD
Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings
USD
Adjustments to Additional Paid in Capital, Stock Split
USD
Adjustments to Additional Paid in Capital, Warrant Issued
USD
Treasury Stock Acquired, Average Cost Per Share
USD/shares
Treasury Stock, Shares
shares
2026-06-30$204.00K$829.59M$-534.00K$-685.60M$143.66M$-534.00K3 month · $7.76M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2026-03-31$204.00K$821.63M$-429.00K$-645.37M$176.04M$-429.00K3 month · $10.73M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2025-12-31$204.00K$811.10M$-87.00K$-608.09M$203.13M$-87.00K12 month · $14.42M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2025-09-30$173.00K$670.22M$-155.00K$-575.85M$94.39M$-155.00K3 month · $3.42M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2025-06-30$173.00K$666.82M$-216.00K$-546.29M$120.48M$-216.00K3 month · $2.67M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2025-03-31$173.00K$664.20M$-632.00K$-515.89M$147.85M$-632.00K3 month · $2.97M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2024-12-31$173.00K$661.28M$-750.00K$-489.25M$171.45M$-750.00K12 month · $9.86M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2024-09-30$172.00K$659.08M$299.00K$-460.21M$199.35M$299.00K3 month · $2.37M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2024-06-30$140.00K$538.43M$-880.00K$-435.96M$101.73M$-880.00K3 month · $2.20M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2024-03-31$140.00K$536.18M$-742.00K$-413.71M$121.86M$-742.00K3 month · $2.26M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2023-12-31$140.00K$533.87M$-271.00K$-393.37M$140.37M$-271.00K12 month · $4.18M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2023-09-30$137.00K$524.62M$-942.00K$-377.27M$146.54M$-942.00K3 month · $995.00K(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2023-06-30$116.00K$448.89M$-619.00K$-360.67M$87.72M$-619.00K3 month · $958.00K(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2023-03-31$116.00K$447.83M$-461.00K$-349.23M$98.25M$-461.00K3 month · $864.00K(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2022-12-31$116.00K$446.94M$-605.00K$-338.67M$107.78M$-605.00K12 month · $2.04M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2022-09-30$116.00K$446.38M$-1.61M$-328.37M$116.51M$-1.61M3 month · $450.00K(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2022-06-30$116.00K$445.93M$-1.02M$-317.99M$127.04M$-1.02M3 month · $456.00K(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2022-03-31$116.00K$445.47M$-291.00K$-308.82M$136.47M$-291.00K3 month · $574.00K(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2021-12-31$116.00K$444.90M$5.00K$-300.52M$144.50M$5.00K12 month · $3.26M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2021-09-30$115.00K$444.04M$285.00K$-289.21M$155.23M$285.00K3 month · $690.00K(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2021-06-30$114.00K$443.34M$592.00K$-278.67M$165.38M$592.00K3 month · $771.00K(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2021-03-31$114.00K$442.25M$485.00K$-267.72M$175.12M$485.00K3 month · $946.00K(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2020-12-31$55.00K$320.89M$942.00K$-257.51M$64.38M$942.00K12 month · $5.11M(m)(m)(m)(m)(m)(m)(m)12 month · $29.00K(m)(m)
2020-09-30$55.00K$320.08M$252.00K$-243.76M$76.63M(m)3 month · $1.93M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2020-06-30$54.00K$316.33M$119.00K$-232.70M$83.80M(m)3 month · $1.18M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2020-03-31$52.00K$310.70M$-128.00K$-223.31M$87.32M(m)3 month · $1.19M(m)(m)(m)(m)(m)(m)(m)3 month · $28.00K(m)(m)
2019-12-31$52.00K$309.56M$-17.00K$-207.89M$101.70M$-17.00K12 month · $4.44M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2019-09-30$42.00K$283.17M$-236.00K$-176.17M$106.80M(m)3 month · $1.15M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2019-06-30$40.00K$276.32M$212.00K$-163.77M$112.80M(m)3 month · $1.15M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2019-03-31$36.00K$243.60M$1.00K$-141.83M$101.80M(m)3 month · $1.00M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2018-12-31$36.00K$237.70M$200.00K$-129.72M$108.22M$200.00K12 month · $3.74M(m)(m)(m)(m)(m)(m)(m)12 month · $78.00K(m)(m)
2018-09-30$36.00K$236.66M$364.00K$-119.20M$117.85M(m)3 month · $1.99M
9 month · $2.79M
(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2018-06-30$32.00K$188.87M$456.00K$-106.64M$82.71M(m)3 month · $392.00K
6 month · $804.00K
(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2018-03-31$32.00K$187.45M$1.27M$-95.05M$93.70M(m)3 month · $412.00K(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2017-12-31$32.00K$186.52M$958.00K$-68.20M$119.31M(m)12 month · $552.00K(m)(m)(m)(m)12 month · $404.00K(m)12 month · $44.44M12 month · $359.00K(m)(m)
2017-09-30$26.00K$135.57M$747.00K$-61.70M$74.64M(m)9 month · $350.00K(m)(m)(m)(m)9 month · $404.00K(m)9 month · $44.44M9 month · $359.00K(m)(m)
2017-06-30$26.00K$134.22M$404.00K$-54.88M$79.77M(m)6 month · $236.00K(m)(m)(m)(m)6 month · $404.00K(m)6 month · $44.44M6 month · $359.00K(m)(m)
2017-03-31$255.00K$321.04M(m)$-316.94M$4.35M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2016-12-31$5.00K$3.12M$-591.00K$-38.41M$-35.88M(m)12 month · $209.00K(m)(m)(m)12 month · $2.64M(m)(m)(m)12 month · $26.00K(m)(m)
2016-09-30$233.00K$317.99M$4.00K$-305.04M$13.19M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2016-06-30$208.00K$313.10M$7.00K$-296.89M$16.43M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2016-03-31$193.00K$306.66M$5.00K$-286.18M$20.68M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2015-12-31$164.00K$298.71M$-17.00K$-274.97M$-27.33M(m)12 month · $153.00K(m)(m)(m)12 month · $2.67M(m)(m)(m)12 month · $392.00K(m)(m)
2015-09-30$164.00K$298.18M$9.00K$-264.81M$33.54M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2015-06-30$164.00K$297.26M$9.00K$-254.90M$42.53M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2015-03-31$159.00K$294.70M$-2.00K$-244.75M$50.11M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2014-12-31$159.00K$293.65M$-25.00K$-235.13M$-18.30M(m)(m)(m)(m)(m)12 month · $2.03M(m)(m)(m)(m)(m)(m)
2014-09-30$127.51K$272.96M$-22.52K$-227.82M$45.25M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2014-06-30$119.84K$270.07M$-17.91K$-219.95M$50.22M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2014-03-31$113.72K$265.50M$-26.18K(m)$52.79M(m)(m)(m)214 month · $34.74K(m)(m)(m)(m)(m)(m)(m)(m)
2013-12-31$103.00K$254.16M$-21.00K$-206.43M$47.81M(m)(m)(m)211 month · $34.74K(m)12 month · $1.60M(m)(m)(m)(m)12 month · 0.00(m)
2013-09-30$102.71K$253.71M$-28.72K(m)$53.06M(m)(m)(m)208 month · $34.74K(m)(m)(m)(m)(m)(m)(m)0.00
2013-06-30$102.71K$253.27M$-8.84K(m)$57.90M(m)(m)(m)205 month · $-34.74K(m)(m)(m)(m)(m)(m)(m)0.00
2013-03-31$47.72K$227.05M$-10.64K(m)$36.55M(m)(m)$1.45K202 month · $-34.74K(m)(m)(m)(m)(m)(m)(m)1.45M
2012-12-31$47.72K$226.70M$-2.19K(m)$41.79M(m)(m)$1.45K199 month · $-34.74K(m)12 month · $1.46M(m)(m)(m)(m)12 month · 0.001.45M
2012-09-30$47.72K$227.20M$-2.22K(m)$46.29M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2012-06-30$47.72K$226.79M$-2.29K(m)$49.08M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2012-03-31$47.72K$226.45M$-2.16K(m)$52.96M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2011-12-31$47.72K$226.12M$-2.30K(m)$56.78M(m)(m)(m)(m)(m)12 month · $866.05K(m)(m)(m)(m)(m)0.00
2011-09-30$26.47K$210.17M$-23.10K(m)$43.15M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2011-06-30$26.47K$209.84M$7.47K(m)$46.40M(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
2011-04-30(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)1 month · 0.00(m)
2010-12-31$15.48K$182.80M$0.00(m)$26.69M(m)(m)(m)(m)(m)12 month · $785.94K(m)(m)(m)(m)(m)(m)
2009-12-31(m)(m)(m)(m)$6.67M(m)(m)(m)(m)(m)12 month · $585.44K(m)(m)(m)(m)(m)(m)
2008-12-31(m)(m)(m)(m)$6.00M(m)(m)(m)(m)(m)12 month · $1.61M(m)(m)(m)(m)(m)(m)
2007-12-31(m)(m)(m)(m)$31.03M(m)(m)(m)(m)(m)12 month · $2.41M(m)(m)(m)(m)(m)(m)
2006-12-31(m)(m)(m)(m)$19.96M(m)(m)(m)(m)(m)12 month · $1.70M(m)(m)(m)(m)(m)(m)
2005-12-31(m)(m)(m)(m)$-7.83M(m)(m)(m)(m)(m)12 month · $994.87K(m)(m)(m)(m)(m)(m)
2004-12-31(m)(m)(m)(m)$12.39M(m)(m)(m)(m)12 month · $1.37M12 month · $524.92K(m)(m)(m)12 month · $86.38K(m)(m)
2003-12-31(m)(m)(m)(m)$4.12M(m)(m)(m)(m)(m)12 month · $286.03K(m)12 month · $37.84K(m)(m)(m)(m)
2002-12-31(m)(m)(m)(m)$-852.73K(m)(m)(m)(m)(m)12 month · $329.30K(m)12 month · $242.40K(m)(m)(m)(m)
2001-12-31(m)(m)(m)(m)$-638.49K(m)(m)(m)(m)(m)(m)(m)12 month · $256.00K(m)12 month · $450.00K(m)(m)
2000-12-31(m)(m)(m)(m)$14.61M(m)(m)(m)(m)(m)(m)(m)12 month · $85.00K(m)(m)(m)(m)
1999-12-31(m)(m)(m)(m)$-1.23M(m)(m)(m)(m)(m)(m)(m)(m)(m)12 month · $212.00K(m)(m)
1998-12-31(m)(m)(m)(m)$-525.26K(m)(m)(m)(m)(m)(m)(m)(m)(m)12 month · $260.00K(m)(m)
1997-12-31(m)(m)(m)(m)$382.21K(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
1996-12-31(m)(m)(m)(m)$-272.62K(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)
1996-06-11(m)(m)(m)(m)$0.00(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)(m)

Similar stocks

Stock NameCountryMarket CapPE Ratio
MoonLake Immunotherapeutics (MLTX)Switzerland$1.031B-5.43
MANNKIND CORP (MNKD)United States$1.058B-30.41
Alto Neuroscience, Inc. (ANRO)United States$1.065B-11.02
Pacira BioSciences, Inc. (PCRX)United States$1.020B69.03
Janux Therapeutics, Inc. (JANX)United States$1.019B-9.15
Corvus Pharmaceuticals, Inc. (CRVS)United States$0.994B-23.25
Amphastar Pharmaceuticals, Inc. (AMPH)United States$1.116B10.93
Kura Oncology, Inc. (KURA)United States$0.967B-3.29
Arbutus Biopharma Corp (ABUS)$0.965B6.19
Seaport Therapeutics, Inc. (SPTX)United States$1.131B